scispace - formally typeset
A

Antonis Fanouriakis

Researcher at National and Kapodistrian University of Athens

Publications -  105
Citations -  3021

Antonis Fanouriakis is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Medicine & Systemic lupus erythematosus. The author has an hindex of 19, co-authored 69 publications receiving 1434 citations. Previous affiliations of Antonis Fanouriakis include University of Crete & Athens State University.

Papers
More filters
Journal ArticleDOI

2019 Update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis

TL;DR: The EULAR recommendations for the management of LN are updated to facilitate homogenization of patient care and transplantation is the preferred kidney replacement option with immunosuppression guided by transplant protocols and/or extra-renal manifestations.
Journal ArticleDOI

Update οn the diagnosis and management of systemic lupus erythematosus

TL;DR: Treatment for SLE usually includes an initial period of high-intensity immunosuppressive therapy to control disease activity, followed by a longer period of less intensive therapy to consolidate response and prevent relapses, including minimisation of glucocorticoid use.
Journal ArticleDOI

Sat0173 a systematic literature review informing the 2019 update of the joint european league against rheumatism and european renal association–european dialysis and transplant association (eular/era-edta) recommendations for the management of lupus nephritis

TL;DR: The findings suggest that the presence of U1RNP/Sm autoantibodies in a cohort of patients who have received treatment with RTX is associated with more frequent musculoskeletal and mucocutaneous involvement and predicts a more favourable response to treatment.
Journal ArticleDOI

Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.

TL;DR: The currently available literature in experimental SLE is summarized, which has led to the recent promising Phase II clinical trial of a JAK inhibitor, and has important therapeutic implications, given the current paucity of targeted therapies.